Department of Orthopaedics, Shengjing Hospital of China Medical University, Sanhao Street No. 36, Heping District, Shenyang, Liaoning, 110004, People's Republic of China.
Department of Orthopedics, Tianjin Baodi Hospital/Baodi Clinical College of Tianjin Medical University, Tianjin, 301800, People's Republic of China.
J Orthop Surg Res. 2021 Oct 18;16(1):615. doi: 10.1186/s13018-021-02721-x.
We aimed to determine the association between serum receptor activator of nuclear factor-kappa B ligand (sRANKL) levels and ankylosing spondylitis (AS) in Chinese patients.
The PubMed, Cochrane Library, Embase, Chinese Biomedical Database, Web of Science, China National Knowledge Infrastructure, VIP, and Wan Fang databases were searched for studies conducted before October 1, 2020, without language restrictions. STATA version 12.0 and Revman version 5.3 were used to analyze the data. The standard mean differences (SMDs) and corresponding 95% confidence intervals (95% CIs) were calculated.
Twelve clinical case-control studies, including 585 patients with AS and 423 healthy controls, were included. The combined SMD for sRANKL suggested that the sRANKL level was significantly higher in Chinese patients with AS than in healthy controls (SMD: 3.27, 95% CI 2.11-4.43, P < 0.00001). Serum RANKL-related factor osteoprotegerin (OPG) levels (SMD: 0.86, 95% CI 0.09-1.64, P < 0.03) were lower in the Chinese patients with AS than in healthy controls, and the RANKL/OPG ratio (SMD = 1.05, 95% CI 0.64-1.46, P < 0.00001) in Chinese patients with AS was approximately the same as that of healthy controls. Subgroup analysis indicated that patients from North and South China had higher sRANKL levels than controls; the sRANKL levels of patients from South China were higher in the subgroup with a Bath Ankylosing Spondylitis Functional Index (BASFI) of > 4 than those of patients in other subgroups. In terms of duration, patients with AS for > 8 years had higher sRANKL levels than health controls. Other subgroup analyses were conducted by region, language, source of control, age, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). In these subgroups, the sRANKL levels were significantly higher in the patients with AS than in healthy controls. The BASFI and BASDAI were sources of heterogeneity.
The sRANKL levels are higher in Chinese patients with AS, especially among those from South China. sRANKL levels may be positively correlated with the pathogenesis of AS among Chinese patients.
我们旨在确定血清核因子-κB 受体激活剂配体(sRANKL)水平与中国患者强直性脊柱炎(AS)之间的关联。
检索了 PubMed、Cochrane 图书馆、Embase、中国生物医学数据库、Web of Science、中国国家知识基础设施、VIP 和万方数据库,检索时间截至 2020 年 10 月 1 日,不限制语言。使用 STATA 版本 12.0 和 Revman 版本 5.3 分析数据。计算标准均数差值(SMD)和相应的 95%置信区间(95%CI)。
纳入了 12 项临床病例对照研究,包括 585 例 AS 患者和 423 例健康对照者。sRANKL 的合并 SMD 表明,中国 AS 患者的 sRANKL 水平明显高于健康对照组(SMD:3.27,95%CI 2.11-4.43,P<0.00001)。中国 AS 患者的血清 RANKL 相关因子骨保护素(OPG)水平(SMD:0.86,95%CI 0.09-1.64,P<0.03)低于健康对照组,而 RANKL/OPG 比值(SMD=1.05,95%CI 0.64-1.46,P<0.00001)与健康对照组相当。亚组分析表明,来自中国北方和南方的患者的 sRANKL 水平高于对照组;来自中国南方的 BASFI>4 分的 AS 患者的 sRANKL 水平高于其他亚组的患者。在病程方面,病程>8 年的 AS 患者的 sRANKL 水平高于健康对照组。其他亚组分析按地区、语言、对照组来源、年龄和 Bath 强直性脊柱炎疾病活动指数(BASDAI)进行。在这些亚组中,AS 患者的 sRANKL 水平明显高于健康对照组。BASFI 和 BASDAI 是异质性的来源。
中国 AS 患者的 sRANKL 水平较高,尤其是来自中国南方的患者。sRANKL 水平可能与中国患者 AS 的发病机制呈正相关。